25+ ME/CFS Phenotyping List
- Aug 26, 2025
- 5 min read
Updated: Apr 2
Clinical and Social Terrain Subtypes in ME/CFS
Executive Summary
For decades, ME/CFS has been treated as a monolith in research, despite overwhelming evidence of heterogeneity across patients. This failure to stratify has been a primary driver of trial collapse, clinical mismanagement, and neglect (Institute of Medicine, 2015; Komaroff, 2021).
The CYNAERA 25 Core ME/CFS Phenotyping List integrates biological, environmental, and social terrain factors into a structured classification system. This list is designed to serve as:
A foundation for adaptive clinical trial design.
A roadmap for individualized care.
A tool for access aware research that includes vulnerable and overlooked populations.
Core Domains of Phenotyping
Formula: Phenotype = Core Axis × Trigger/Modulator + Functional Signature
1. Energy Dysregulation Axis
PEM-Dominant Classic – exertion → multi-day crash.
Cognitive PEM – mental effort triggers relapse.
Delayed-Onset PEM – crash 24–72h after trigger.
Remission-Relapse Oscillator – alternating stable & crash states.
Adrenergic Reserve – compensates via stress hormones, then collapse.
2. Autonomic & Circulatory Axis
POTS-Dominant – tachycardia, orthostatic intolerance.
Orthostatic Intolerance (Non-Tachycardic) – dizziness/fatigue without HR spike.
Blood Volume/Perfusion Variant – low plasma volume, poor circulation.
Baroreflex Dysregulation – unstable BP with gravity stressors.
3. Neuro-Immune & Sensory Axis
Neuroinflammatory Brain Fog – cognitive slowing, cytokine-driven.
Sensory Overload Dominant – light, sound, smell hypersensitivity.
Cognitive-Motor Coordination Decline – motor planning + thinking impaired.
Visual-Spatial Lag – delayed motion/space processing.
4. Hormonal & Endocrine Axis
Cycle-Triggered PEM – symptom worsening with menstruation.
Estrogen Withdrawal Subtype – crashes during peri-/post-menopause.
HPA Axis Dysfunction – adrenal/hypothalamic imbalance.
Postpartum Collapse – immune-hormonal breakdown post-birth.
5. Immune, Infection & Reactivation Axis
EBV/HHV-6 Reactivation Subtype – episodic flares.
Low NK Cell Immunodeficiency – recurrent infections, poor clearance.
Post-Viral Chronic Onset – mono/flu/COVID as initiating trigger.
Steroid-Triggered Relapser – immune suppression → viral rebound.
6. Sleep & Pain Axis
Non-Restorative Sleep Core – poor restorative function despite hours slept.
Sleep-Wake Reversal – flipped circadian cycles.
Migraine/Pain-Dominant – headaches, muscle spasm, neuropathic pain.
Neuro-Excitability Subtype – EEG abnormalities, seizure-like flares.
7. Social, Demographic & Access Constrained
These don’t define phenotypes alone but modify severity, access, and progression:
BIPOC Misdiagnosed Variant – dismissed as depression/anxiety.
Low-Income/Access Barrier – worsened by untreated flares, poor care.
Pediatric Misattribution – mislabeled as anxiety/behavioral.
Men Misdiagnosed as Burnout – gendered undercounting.
Mold/Housing Overlay – environmental driver of relapse.
Food Insecurity Overlay – malnutrition worsening PEM.
Why This Matters
Clinical Trials: Stratification into these phenotypes prevents dilution of signals, reduces dropouts, and enables biomarker-linked subgrouping (Fluge & Mella, 2019; Bateman et al., 2021).
Clinical Care: Recognizes terrain-specific vulnerabilities such as hormonal modulation, reactivation triggers, or environmental stressors (Hornig et al., 2015).
Accuracy: Includes structural and social barriers (late diagnosis, BIPOC misclassification, food insecurity), which are routinely excluded from research yet shape disease trajectory (Wong et al., 2023).
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library and ME/CFS Library is also a great resource.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
References
Bateman, L., Rowe, P. C., & Montoya, J. G. (2021). Post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Pediatrics, 9, 707819.
Fluge, Ø., & Mella, O. (2019). Clinical trials of B-cell depletion therapy for myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Immunology, 10, 1225.
Hornig, M., Montoya, J. G., Klimas, N., Levine, S., Felsenstein, D., Bateman, L., ... & Lipkin, W. I. (2015). Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Science Advances, 1(1), e1400121.
Institute of Medicine (IOM). (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press.
Komaroff, A. L. (2021). Advances in understanding the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome. Nature Reviews Disease Primers, 7, 68.
Wong, T. L., Weitz, J. S., Adinig, C., et al. (2023). Findings from an online survey of people with long COVID: Characterization and impact. medRxiv.
Comments